The Effect of Vitamin E-coated Polysulfone Membrane on Oxidative Stress, Inflammation and Monocytes in Critically Ill Patients in CRRT

Renal Failure Clinical Trial

— Vitabrane E  

Official title:

The Effect of Vitamin E-coated Polysulfone Membrane on Oxidative Stress, Inflammation and Monocytes in Critically Ill Patients in CRRT: a Pilot, Randomized, Double-blinded, No-profit, Clinical Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03489759
• Other study ID #: 79/16A
• Status: Recruiting
• Phase: N/A
• Start date: March 13, 2018
• Est. completion date: December 13, 2019

Study information

• Verified date: April 2019
• Source: St. Bortolo Hospital
• Contact: Silvia De Rosa, MD
• Phone: +393933098583
• Email: derosa.silvia[@]ymail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study evaluate the effect of a membrane in polysulfone covered with vitamin E (ViE15-A, ASAHI Kasey, Tokyo, Japan) versus non-vitamin E polysulfone membrane (REXEED-15A, ASAHI Kasey, Tokyo, Japan) in critically ill patients admitted to intensive care undergoing continuous extracorporeal dialysis (CRRT).

The current randomized study is designed to assess the effect on the levels of oxidative stress, pro and anti-inflammatory cytokines and the mode and amount of death of monocytic cell lines using ViE 15-A in comparison withe REXEED-15A.

The investigators hypothezise that the ViE15-A versus REXEED-15A will have different effect on the levels of oxidative stress, pro and anti-inflammatory cytokines and the mode and amount of death of monocytic cell lines.

Description:

The study evaluate the effect of a membrane in polysulfone covered with vitamin E (ViE15-A, ASAHI Kasey, Tokyo, Japan) on the levels of oxidative stress, pro and anti-inflammatory cytokines and the mode and amount of death of monocytic cell lines in critically ill patients admitted to intensive care undergoing continuous extracorporeal dialysis (CRRT).

This membrane will be compared with a non-vitamin E polysulfone membrane (REXEED-15A, ASAHI Kasey, Tokyo, Japan) and already intended for use in continuous renal support therapy.

The current randomized study is designed to assess the effect on the levels of oxidative stress, pro and anti-inflammatory cytokines and the mode and amount of death of monocytic cell lines using ViE 15-A in comparison withe REXEED-15A.

Precisely, will be evaluated

1. the effect of the filter on the reduction of the plasma levels of two pro-inflammatory cytokines (IL-1β and IL-6) and of two anti-inflammatory cytokines (IL-10, IL-8);

2. the analysis of the life modality of the monocytic cells: the patient's plasma will be used, incubated for 24 hours with U937 cells (monocyte precursor cells), necrosis cells and the percentage of apoptotic cells. The apoptotic cells will also evaluate the apoptotic pathway (evaluation of activated caspases) that led to cell death. The differences that are highlighted in the two different sampling moments become expressed Δ% with respect to the initial value Secondary outcomes will be to evaluate the clinical outcomes (haemodynamic and hematochemical parameters) in the short and long term deriving from the application of a membrane with vitamin E; for this reason, for the whole duration of the extracorporeal dialysis therapy, the same filter assigned to the patient at the time of enrollment will be used.

All the other parameters of the extracorporeal treatment that can influence the results will be standardized; in particular, the flows will be fixed according to the dialysis dose criteria and re-infusion methods according to the table in the paragraph "treatment characteristics".

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: December 13, 2019
• Est. primary completion date: September 13, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age > 18 years

• Acute Kidney Injury

• ICU patients with clinical indication for Continuous Renal Replacement Therapy

• Clinical decision to begin CVVH for at least 24 hours with high flux filter (defined as membranes with an ultrafiltration coefficient KUF > 25ml/Kg/h)

• Obtain the informed consent

Exclusion Criteria:

• Hemodialysis patients, peritoneal dialysis patients and transplant recipient;

• Hypothermia (T < 36°C)

• Regional Anticoagulation with Citrate

• Septic Shock;

• Neoplasm in Chemotherapy

• Extra-Corporeal Membrane Oxygenation

• Cardio Circulatory Arrest

• Autoimmune disease or immunosuppressed patients;

• Life expectancy < 24 hr

• Pregnancy;

• Informed Consent refused by the patient or surrogate decision-maker

Related Conditions & MeSH terms

• Acute Kidney Injury
• Critical Illness
• Inflammation
• Renal Failure
• Renal Insufficiency
• Renal Insufficiency, Acute

Intervention

Device:
• ViE15-A
The type of dialytic treatment that will be used during the study will be continuous venous hemofiltration (CVVH-Continuous veno-venous hemofiltration). The filter will be ViE15-A.
• REXEED-15A
The type of dialytic treatment that will be used during the study will be continuous venous hemofiltration (CVVH-Continuous veno-venous hemofiltration). The filter will be REXEED-15A.

Locations

Country	Name	City	State
Italy	San Bortolo Hospital	Vicenza

Sponsors (1)

Lead Sponsor	Collaborator
St. Bortolo Hospital

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Copper/Zinc	In vivo comparison of ROS concentrations in two groups	change from 24 to 72 hours
Primary	Superoxide Dismutas	In vivo comparison of ROS concentrations in two groups	change from 24 to 72 hours
Primary	Endogenous peroxidase activity	In vivo comparison of ROS concentrations in two groups	change from 24 to 72 hours
Primary	Nitric Oxide	In vivo comparison of ROS concentrations in two groups	change from 24 to 72 hours
Primary	Viability	Ex vivo comparison of relative decrease of monocytes cell line incubated in plasma	change from 24 to 72 hours
Primary	Apoptosis	Ex vivo comparison of relative decrease of monocytes cell line incubated in plasma	change from 24 to 72 hours
Primary	Necrosis	Ex vivo comparison of relative decrease of monocytes cell line incubated in plasma	change from 24 to 72 hours
Primary	Interleukine-6	In vivo comparison of relative reductions of inflammatory cytokines concentrations in two groups	change from 24 to 72 hours
Primary	Interleukine -10	In vivo comparison of relative reductions of inflammatory cytokines concentrations in two groups	change from 24 to 72 hours
Primary	Interleukine-18	In vivo comparison of relative reductions of inflammatory cytokines concentrations in two groups	change from 24 to 72 hours
Secondary	Comparison of CRRT-free days from enrollment to ICU discharge in two groups	The assessment of the effect of both hemofilters on short term clinical renal outcomes	7 days
Secondary	Comparison of mechanical Ventilation-free days from enrollment to ICU discharge in two groups	The assessment of the effect of both hemofilters on short term clinical renal outcomes	7 days
Secondary	Comparison of vasopressor drugs-free days in two groups	The assessment of the effect of both hemofilters on short term clinical renal outcomes	7 days
Secondary	Comparison of ICU length of stay in two groups	The assessment of the effect of both hemofilters on short term clinical renal outcomes	7 days
Secondary	Comparison of renal recovery in two groups	The assessment of the effect of both hemofilters on short term clinical renal outcomes	7 days
Secondary	Comparison of CRRT-free days from enrollment to hospital discharge in two groups	The assessment of the effect of both hemofiltes on long term clinical renal outcomes	90 days
Secondary	Comparison of need of (Intermittent Hemodialysis) IHD at hospital discarge in patients treated with vitamine E-coated membrane and non-vitamin E-coated membrane	The assessment of the effect of both hemofiltes on long term clinical renal outcomes	90 days
Secondary	Comparison of renal recovery at hospital discharge in two groups	The assessment of the effect of both hemofiltes on long term clinical renal outcomes	90 days